Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Upcoming IPO
Afc Gamma, Inc. (AFCG)
Property Solutions Acquisition II (PSAGU)
Khosla Ventures Acquisition Co. (KVSA)
Twin Ridge Capital Acquisition (TRCA.U)
Rxr Acquisition (RXRAU)
Interprivate II Acquisition (IPVA.U)
Interprivate III Financial Partners (IPVF.U)
Aurora Acquisition Corp. (AURCU)
ALTIMAR ACQUISITION CORP. III (ATAQU)
Lerer Hippeau Acquisition Corp. (LHAA)
Universe Pharmaceuticals (UPC)
Roblox Corporation (RBLX)
First High-school Education Group Co., Ltd. (FHS)
Coupang, Inc. (CPNG)
Hayward Holdings, Inc. (HAYW)
Priced IPO
Innovage Holding Corp (INNV)
Oscar Health, Inc. (OSCR)
Score Media And Gaming, Inc. (SCR)
Briacell Therapeutics Corp. (BCTX)
Clip Interactive, LLC (AUDD)
Greenbox Pos (GBOX)
Virpax Pharmaceuticals, Inc. (VRPX)
Urban-gro (UGRO)
Neximmune, Inc. (NEXI)
Longeveron (LGVN)
Talis Biomedical Corporation (TLIS)
Decibel Therapeutics, Inc. (DBTX)
Loandepot, Inc. (LDI)
Bumble, Inc. (BMBL)
Apria, Inc. (APR)
Signify Health, Inc.. (SGFY)
Bioventus Inc. (BVS)
Biophytis SA (BPTS)
Vallon Pharmaceuticals (VLON)
Viant Technology Inc. (DSP)
More companies

Cullinan Oncology, Llc (CGEM)

Sector - Healthcare

Price chart

+104.76%
Return from IPO

Company News

IPO Profile

About company

They are a biopharmaceutical company focused on developing a diversified pipeline of targeted oncology and immuno-oncology therapies with transformative potential for cancer patients. Their lead candidate, CLN-081, is an orally available small molecule designed as a next generation, irreversible epidermal growth factor receptor, or EGFR, inhibitor that is designed to selectively target cells expressing mutant EGFR variants, including EGFR exon 20 insertion, or EGFRex20ins, mutations, with relative sparing of cells expressing wild type EGFR. They are currently evaluating CLN-081 as a treatment for non-small cell lung cancer, or NSCLC, in adult patients with EGFRex20ins mutations in a Phase 1/2a trial. Their most advanced immuno-oncology therapeutic candidates include CLN-049, a bispecific antibody targeting FLT3 and CD3; and CLN-619, a monoclonal antibody designed to stimulate natural killer, or NK, and T cell responses by engaging a unique target, MICA/B. They intend to initially develop CLN-049 for the treatment of acute myeloid leukemia, or AML, and CLN-619 for the treatment of solid tumors. In addition, through their AMBER platform, they are developing CLN-617, a fusion protein uniquely combining, in a single agent, two potent antitumor cytokines, interleukin-2, or IL-2, and interleukin-12, or IL-12, fused with a collagen-binding domain designed to enable tumor retention for the treatment of solid tumors.
Industry
Biological Products (no Diagnostic Substances)
CEO CFO
Owen Hughes Jeffrey Trigilio
Employees Founded
17 2016

Contacts

Address: One Main Street, Suite 520, Cambridge, MA 02142, US

Telephone: (617) 410-4650

Web page: http://www.cullinanoncology.com

IPO information

Expected Date 1/8/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range $17.00-$19.00
Share prices ($)

Shares & Volumes

Shares Initial (MM) 8.33
Shares Revised (MM) 11.9
Expected offer amount (MM) $195
Realized offer amount(MM) $249.9

Financial Data (last reporting year)

Market Cap (MM) $680.94
Revenues (MM) $0
Net Income (Loss) (MM) $-23.0

Voting

What do you think will happen with the CGEM share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Morgan Stanley

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Morgan Stanley/ SVB Leerink/ Evercore ISI
CO-Managers
HC Wainwright

Sector: Healthcare

Tweets about $CGEM

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats